Evidence map›Paper›PMID 36721107›Full record

ArticleBMC neuroscience2023

Cudraflavone B induces human glioblastoma cells apoptosis via ER stress-induced autophagy.

Jinlin Pan, Rongchuan Zhao, Caihua Dong, Jiao Yang, Ruobing Zhang, Minxuan Sun, Nafees Ahmad, Yuanshuai Zhou, Yanxiang Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jinlin PanSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Rongchuan ZhaoSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Caihua DongSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Jiao YangInstitute of Clinical Medicine Research, Suzhou Science & Technology Town Hospital, Suzhou, 215153, China.
Ruobing ZhangJiangsu Key Lab of Medical Optics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Keling Road No.88, Suzhou, 215163, China.
Minxuan SunJiangsu Key Lab of Medical Optics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Keling Road No.88, Suzhou, 215163, China.
Nafees AhmadInstitute of Biomedical and Genetic Engineering, Islamabad, Pakistan.
Yuanshuai ZhouSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China. zhouys@sibet.ac.cn.
Yanxiang LiuDepartment of Pathology, Suzhou Science & Technology Town Hospital, No.1, Li Jiang Road, High-Tech District, Suzhou, 215153, China. liu-yanxiang@foxmail.com.
Chinese Academy of Sciences · CNSuzhou Institute of Biomedical Engineering and Technology · CNInstitute of Biomedical and Genetic Engineering · PKSuzhou University of Science and Technology · CNUniversity of Science and Technology of China · CN

Funding

Innovative and Entrepreneurial Talent Program of Jiangsu for Guohua Shi team, the China Postdoctoral Science Foundation 2020M671599National Natural Science Foundation of China 81903028Projects of International Cooperation of Jiangsu Province BZ2020004Suzhou Medical Innovation Applied Research Project SKYD2022090Suzhou municipal key clinical disciplines cultivate program SZFCXK202142
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is the most common malignant intracranial tumor with a low survival rate. However, only few drugs responsible for GBM therpies, hence new drug development for it is highly required. The natural product Cudraflavone B (CUB) has been reported to potentially kill a variety of tumor cells. Currently, its anit-cancer effect on GBM still remains unknown. Herein, we investigated whether CUB could affect the proliferation and apoptosis of GBM cells to show anti-GBM potential.

resultsCUB selectively inhibited cell viability and induced cell apoptosis by activating the endoplasmic reticulum stress (ER stress) related pathway, as well as harnessing the autophagy-related PI3K/mTOR/LC3B signaling pathway. Typical morphological changes of autophagy were also observed in CUB treated cells by microscope and scanning electron microscope (SEM) examination. 4-Phenylbutyric acid (4-PBA), an ER stress inhibitor, restored the CUB-caused alteration in signaling pathway and morphological change.

conclusionsOur finding suggests that CUB impaired cell growth and induced cell apoptosis of glioblastoma through ER stress and autophagy-related signaling pathways, and it might be an attractive drug for treatment of GBM.

Indexed as

GlioblastomaApoptosisAutophagyEndoplasmic Reticulum StressFlavonoidsHumanscudraflavone BFlavonoidsAutophagyEndoplasmic reticulum stressGBMUnfolded protein response

Identifiers

PMID36721107
PMCPMC9890863
OpenAlexW4318705716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.